Autoimmune cytopenias in chronic lymphocytic leukemia

American Journal of Hematology

Volumn 89, Issue 11, 2014, Pages 1055-1062

  Visco, Carlo ^a   Barcellini, Wilma ^b   Maura, Francesco ^b,c   Neri, Antonino ^b,c   Cortelezzi, Agostino ^b,c   Rodeghiero, Francesco ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; MONOCLONAL ANTIBODY; MYCOPHENOLATE MOFETIL; PREDNISONE; RITUXIMAB;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CYTOPENIA; GRANULOCYTOPENIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REVIEW;

EID: 85006474631     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23785     Document Type: Review

References (114)

1. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
2. Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: Autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998;25:80–97.
3. Ebbe S, WittelS B, Dameshek W. Autoimmune thrombocytopenic purpura (“ITP” type) with chronic lymphocytic leukemia. Blood 1962;19:23–37.
4. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:230–239.
5. Hodgson K, Ferrer G, Pereira A, et al. Autoimmune cytopenia in chronic lymphocytic leukaemia: Diagnosis and treatment. Br J Haematol 2011;154:14–22.
6. Visco C, Rodeghiero F. Immune thrombocytopenia in lymphoproliferative disorders. Hematol Oncol Clin North Am 2009;23:1261–1274.
7. Zent CS, Kay NE. Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010;23:47–59.
8. Zent CS, Ding W, Reinalda MS, et al. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: Changes in clinical presentation and prognosis. Leuk Lymphoma 2009;50:1261–1268.
9. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815.
10. Dameshek W. Chronic lymphocytic leukemia–An accumulative disease of immunolgically incompetent lymphocytes. Blood 1967;29:84.
11. Galton DA. The pathogenesis of chronic lymphocytic leukemia. Can Med Assoc J 1966;94:1005–1010.
12. Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993;81:2475–2487.
13. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 1986;39:713–716.
14. Beaume A, Brizard A, Dreyfus B, et al. High incidence of serum monoclonal Igs detected by a sensitive immunoblotting technique in B-cell chronic lymphocytic leukemia. Blood 1994;84:1216–1219.
15. Broker BM, Klajman A, Youinou P, et al. Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J Autoimmun 1988;1:469–481.
16. Stevenson FK, Hamblin TJ, Stevenson GT, et al. Extracellular idiotypic immunoglobulin arising from human leukemic B lymphocytes. J Exp Med 1980;152:1484–1496.
17. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: Cautionary notes and additional considerations and possibilities. Blood 2011;117:1781–1791.
18. Burger JA, Ghia P, Rosenwald A, et al. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367–3375.
19. Deaglio S, Aydin S, Grand MM, et al. CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol Med 2010;16:87–91.
20. Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37–50.
21. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102:1515–1525.
22. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–1854.
23. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625–1638.
24. Herve M, Xu K, Ng YS, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 2005;115:1636–1643.
25. Maura F, Visco C, Falisi E, et al. B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. Am J Hematol 2013;88:32–36.
26. Visco C, Giaretta I, Ruggeri M, et al. Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia. Leukemia 2007;21:1092–1093.
27. Visco C, Ruggeri M, Laura EM, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008;111:1110–1116.
28. Visco C, Novella E, Peotta E, et al. Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status. Haematologica 2010;95:1230–1232.
29. Visco C, Maura F, Tuana G, et al. Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors. Clin Cancer Res 2012;18:1870–1878.
30. Mockridge CI, Potter KN, Wheatley I, et al. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007;109:4424–4431.
31. Vanura K, Le T, Esterbauer H, et al. Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes. Haematologica 2008;93:1912–1916.
32. Bomben R, Dal BM, Capello D, et al. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. Br J Haematol 2009;144:492–506.
33. Maura F, Cutrona G, Fabris S, et al. Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. PLoS One 2011;6:e24313.
34. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 2007;109:259–270.
35. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3–21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003;101:4952–4957.
36. Widhopf GF, Rassenti LZ, Toy TL, et al. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 2004;104:2499–2504.
37. Galletti J, Canones C, Morande P, et al. Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: possible role as initiators of autoimmune hemolytic anemia. J Immunol 2008;181:3674–3683.
38. Hall AM, Vickers MA, McLeod E, et al. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 2005;105:2007–2015.
39. Gorgun G, Holderried TA, Zahrieh D, et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005;115:1797–1805.
40. Ramsay AG, Gribben JG. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. Haematologica 2009;94:1198–1202.
41. Riches JC, Ramsay AG, Gribben JG. T-cell function in chronic lymphocytic leukaemia. Semin Cancer Biol 2010;20:431–438.
42. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005;106:2018–2025.
43. D'Arena G, Rossi G, Vannata B, et al. Regulatory T-cells in chronic lymphocytic leukemia and autoimmune diseases. Mediterr J Hematol Infect Dis 2012;4:e2012053.
44. Lad DP, Varma S, Varma N, et al. Regulatory T-cells in B-cell chronic lymphocytic leukemia: Their role in disease progression and autoimmune cytopenias. Leuk Lymphoma 2013;54:1012–1019.
45. Strati P, Caligaris-Cappio F. A matter of debate in chronic lymphocytic leukemia: Is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy? Curr Opin Oncol 2011;23:455–460.
46. Ward FJ, Hall AM, Cairns LS, et al. Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia. Blood 2008;111:680–687.
47. Wright GP, Ehrenstein MR, and Stauss HJ. Regulatory T-cell adoptive immunotherapy: Potential for treatment of autoimmunity. Expert Rev Clin Immunol 2011;7:213–225.
48. Grandjenette C, Kennel A, Faure GC, et al. Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells. Haematologica 2007;92:1279–1281.
49. Muzio M, Bertilaccio MT, Simonetti G, et al. The role of toll-like receptors in chronic B-cell malignancies. Leuk Lymphoma 2009;50:1573–1580.
50. Barcellini W, Imperiali FG, Zaninoni A, et al. Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: Relationship with infections, autoimmunity and disease progression. Leuk Lymphoma 2014 [Epub ahead of print].
51. Barcellini W, Capalbo S, Agostinelli RM, et al. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica 2006;91:1689–1692.
52. Leporrier M, Reman O, Troussard X. Pure red-cell aplasia with fludarabine for chronic lymphocytic leukaemia. Lancet 1993;342:555.
53. Montillo M, Tedeschi A, Leoni P. Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia. Leuk Lymphoma 1994;15:187–188.
54. Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998;16:1885–1889.
55. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
56. Byrd JC, Hertler AA, Weiss RB, et al. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Ann Oncol 1995;6:300–301.
57. Otton SH, Turner DL, Frewin R, et al. Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukaemia. Br J Haematol 1999;106:261–262.
58. Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood 2011;118:6299–6305.
59. Reda G, Maura F, Gritti G, et al. Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia. Am J Hematol 2012;87:936–937.
60. Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008;141:615–621.
61. Petz LD, Garratty G. Immune Hemolytic Anemias, 2nd ed. Philadelphia: Churchill Livingstone; 2004.
62. Kamesaki T, Toyotsuji T, Kajii E. Characterization of direct antiglobulin test-negative autoimmune hemolytic anemia: A study of 154 cases. Am J Hematol 2013;88:93–96.
63. Toyotsuji T, Kamesaki T, Kajii E. Coombs-positive and negative autoimmune hemolytic anemia might immunologically differ. Rinsho Ketsueki 2011;52:461.
64. Engelfriet CP, von dem Borne AEG, Beckers D, et al. Immune destruction of red cells. In: Bell CA, editor. A Seminar on Immune-Mediated Cell Destruction. Washington, DC: American Association of Blood Banks; 1981. pp 93–130.
65. Barcellini W, Montesano R, Clerici G, et al. In vitro production of anti-RBC antibodies and cytokines in chronic lymphocytic leukemia. Am J Hematol 2002;71:177–183.
66. Bartolmas T, Salama A. A dual antiglobulin test for the detection of weak or nonagglutinating immunoglobulin M warm autoantibodies. Transfusion 2010;50:1131–1134.
67. Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenias in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 2010;96:752–761.
68. Visco C, Cortelezzi A, Moretta F, et al. Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: Is stage C always stage C? Leuk Lymphoma 2013.
69. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009;113:2386–2393.
70. Hodgson K, Ferrer G, Montserrat E, et al. Chronic lymphocytic leukemia and autoimmunity: A systematic review. Haematologica 2011;96:752–761.
71. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190–4207.
72. Tandra P, Krishnamurthy J, Bhatt VR, et al. Autoimmune cytopenias in chronic lymphocytic leukemia, facts and myths. Mediterr J Hematol Infect Dis 2013;5:e2013068.
73. Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood 2002;99:1092–1094.
74. Mouthon L, Guillevin L, Tellier Z. Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev 2005;4:264–269.
75. Fioredda F, Calvillo M, Bonanomi S, et al. Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica). Am J Hematol 2012;87:238–243.
76. Viny AD, Lichtin A, Pohlman B, et al. Chronic B-cell dyscrasias are an important clinical feature of T-LGL leukemia. Leuk Lymphoma 2008;49:932–938.
77. Wolach O, Bairey O, and Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010;89:308–318.
78. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003;348:2691–2694.
79. Dunleavy K, Tay K, Wilson WH. Rituximab-associated neutropenia. Semin Hematol 2010;47:180–186.
80. Rao VK, Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. Blood 2011;118:5741–5751.
81. Hwang K, Park CJ, Huh HJ, et al. Flow cytometric detection of neutrophil-associated immunoglobulin in patients with or without neutropenia and establishment of the reference interval. Ann Clin Lab Sci 2011;41:144–149.
82. Ito T, Taniuchi S, Tsuji S, et al. Diagnosis of autoimmune neutropenia by neutrophil-bound IgG and IgM antibodies. J Pediatr Hematol Oncol 2011;33:552–555.
83. Bux J, Behrens G, Jaeger G, et al. Diagnosis and clinical course of autoimmune neutropenia in infancy: Analysis of 240 cases. Blood 1998;91:181–186.
84. Fioredda F, Calvillo M, Bonanomi S, et al. Congenital and acquired neutropenia consensus guidelines on diagnosis from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica). Pediatr Blood Cancer 2011;57:10–17.
85. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208:1389–1401.
86. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012;119:2854–2862.
87. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365:2497–2506.
88. Binet JL, Lepoprier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977;40:855–864.
89. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219–234.
90. Shvidel L, Tadmor T, Braester A, et al. Pathogenesis, prevalence, and prognostic significance of cytopenias in chronic lymphocytic leukemia (CLL): A retrospective comparative study of 213 patients from a national CLL database of 1,518 cases. Ann Hematol 2013;92:661–667.
91. Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000;95:2786–2792.
92. Dearden C, Wade R, Else M, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: A beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008;111:1820–1826.
93. Zanotti R, Frattini F, Ghia P, et al. ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients. Am J Hematol 2010;85:494–498.
94. Laurenti L, Vannata B, Innocenti I, et al. The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis 2013;5:e2013027.
95. Aleem A, Alaskar AS, Algahtani F, et al. Rituximab in immune thrombocytopenia: Transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients. Int J Hematol 2010;92:283–288.
96. Bruserud O, Havardstein K. Should low-dose mycophenolate mofetil be used to prolong the response after rituximab therapy in patients with immune thrombocytopenic purpura? A case report. Hematology 2009;14:224–226.
97. Cooper N, Evangelista ML, Amadori S, et al. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? Curr Opin Hematol 2007;14:642–646.
98. D'Arena G, Laurenti L, Capalbo S, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006;81:598–602.
99. Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood 2012;119:3691–3697.
100. Kaufman M, Limaye SA, Driscoll N, et al. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:892–899.
101. Michallet AS, Rossignol J, Cazin B, et al. Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leuk Lymphoma 2011;52:1401–1403.
102. Rossignol J, Michallet AS, Oberic L, et al. Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia 2011;25:473–478.
103. Bowen DA, Call TG, Shanafelt TD, et al. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma 2010;51:620–627.
104. Osterborg A, Karlsson C, Lundin J. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2009;4:47–53.
105. D'Arena G, Capalbo S, Laurenti L, et al. Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: A retrospective study of 21 patients. Eur J Haematol 2010;85:502–507.
106. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641–648.
107. D'Arena G, Cascavilla N. Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia. Leuk Lymphoma 2011;52:701–704.
108. Gudbrandsdottir S, Frederiksen H, Hasselbalch H. Thrombopoietin-receptor agonists in haematological disorders: The Danish experience. Platelets 2012;23:423–429.
109. Koehrer S, Keating MJ, Wierda WG. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia 2010;24:1096–1098.
110. Chikkappa G, Pasquale D, Zarrabi MH, et al. Cyclosporine and prednisone therapy for pure red cell aplasia in patients with chronic lymphocytic leukemia. Am J Hematol 1992;41:5–12.
111. Gotic M, Basara N, Rolovic Z, et al. Successful treatment of refractory pure red cell aplasia secondary to chronic lymphocytic leukaemia with cyclosporine A: Correlation between clinical and in vitro effects. Nouv Rev Fr Hematol 1994;36:307–309.
112. Narra K, Borghaei H, Al-Saleem T, et al. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: Report of two cases and review of the literature. Leuk Res 2006;30:109–114.
113. Rodon P, Breton P, Courouble G. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H. Eur J Haematol 2003;70:319–321.
114. Ru X, Liebman HA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol 2003;123:278–281.